TOPAMAX is indicated for: Epilepsy: initial monotherapy in patients ≥2 years of age with partial onset or primary generalized tonic-clonic seizures (1
The OCP review finds: “the PK bridging acceptable and recommends the approval of topiramate oral solution, 25 mg/mL for the treatment of monotherapy epilepsy and
Sodium valproate is believed to produce plasma levels around 30% lower than corresponding doses of semi-sodium valproate
In order to have successful quantification of TPM, appropriate tuning parameters for ESI-mode were optimized for detection of the precursor and product ions
75 mg/topiramate 23 mg once daily for 14 days
In 2000, the FDA approved the use of the oral formulation as adjunctive therapy for the treatment of
One of Topiramate
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates
5 mg/46 mg dose (2
Where there is a low risk of toxicity, onward monitoring may then be reduced to 3-monthly as a minimum, after discussion with the relevant consultant
The International League Against Epilepsy (ILAE) determines seizure type on the basis of
Therefore, changes in cotherapy with these medications (phenytoin, carbamazepine, posaconazole, or phenobarbital) may require dose adjustment of topiramate, and therapeutic drug monitoring could assist with this
Topiramate is a compound that belongs to the family of medications called antiepileptic drugs (AEDs)
In this study, for the first time, the aim was to provide a systematic literature review regarding this issue
Periodically monitor renal function, serum electrolytes, serum glucose, volume status, blood pressure, and diuretic effect
A 4-week study of prospective open-label monotherapy or adjunctive therapy 43 was conducted in civilians with chronic PTSD (N = 33)
feeling agitated or restless
Topiramate is an anticonvulsant lowering the seizure threshold stabilizing membrane by acting on high-voltage-activated calcium channels and voltage-gated sodium channels and its augmenting effect on GABA-A receptors
Reduce P-gp substrate dose if needed
3) • Metabolic acidosis: baseline and periodic measurement of serum Oral
5 mg/topiramate 46 mg once daily; if a ≥3% weight loss not achieved, discontinue drug or Palpacuer C, Duprez R, Huneau A, et al
The dosage should then be increased in increments of 25mg/day at one-week intervals
Select one: Alprazolam